Fast Market Research announces the availability of the new Global Markets Direct report, "Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2017", on their comprehensive research portal
Boston, MA -- (SBWIRE) -- 06/30/2017 -- Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The latest report Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2017, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 1 and 6 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology which include indications Alzheimer's Disease, Schizophrenia, Psychosis, Amnesia, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Epilepsy, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Parkinson's Disease, Presbyopia, Rett Syndrome and Sialorrhoea.
Get More Details on this Report and a Full Table of Contents at Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2017
Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
-The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)
-The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects
-The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics
Reasons to Get this Report
-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)
-Identify the use of drugs for target identification and drug repurposing
-Identify potential new clients or partners in the target demographic
-Develop strategic initiatives by understanding the focus areas of leading companies
-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
-Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned in this Report: Anavex Life Sciences Corp, AstraZeneca Plc, Heptares Therapeutics Ltd, Karuna Pharmaceuticals Inc, NeuroHealing Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Drug Pipeline research reports at Fast Market Research
You may also be interested in these related reports:
-Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017
-Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H1 2017
-Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H1 2017
-Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2017
-Dementia - Pipeline Review, H1 2017